Salute e Benessere
Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
RN3161, a novel siRNA developed through Rona's proprietary GAIA™ platform, targets INHBE to reduce fat while preserving lean mass, setting it apart from existing treatments. Engineered with optimized GalNAc-conjugated delivery and chemical modifications, it minimizes off-target risks and demonstrated more than 90% INHBE mRNA knockdown in monkeys with a low single dose. RN3161's long-lasting gene silencing supports Q6M to Q12M dosing, enhancing patient adherence and suitability for long-term obesity management. As the fourth clinical candidate from GAIA™, RN3161 underscores Rona's consistent excellence to advance innovative RNAi medicines from bench to bedside.
, said,
, added,
Rona Therapeutics is a pioneering RNAi platform company dedicated to addressing cardiometabolic diseases and obesity worldwide. Rona's pipeline is fueled by highly effective and proprietary liver and extra-hepatic delivery platforms. The company has raised $100M USD since inception.
View original content:https://www.prnewswire.co.uk/news-releases/rona-therapeutics-announces-ind-filing-of-rn3161-a-highly-potent-and-durable-inhbe-sirna-for-obesity-302555712.html